Lexaria Bioscience raises $3.5 million in registered direct offering

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a registered direct offering to raise approximately $3.5 million in gross proceeds. The company will sell 2,661,600 shares of common stock at $1.315 per share, priced at-the-market under Nasdaq rules.

The offering includes a concurrent private placement of warrants to purchase up to 2,661,600 shares of common stock. The warrants carry an exercise price of $1.19 per share, are immediately exercisable, and expire five years from the effectiveness of the resale registration statement.

H.C. Wainwright & Co. serves as the exclusive placement agent for the offering. The transaction is expected to close on or about December 16, 2025, subject to customary closing conditions.

Lexaria stated it intends to use the net proceeds to advance research and development efforts, fund working capital, and support general corporate purposes. The company operates in drug delivery platforms with its DehydraTECH technology.

The common shares are being offered under a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. The warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act and have not been registered.

Lexaria holds 56 granted patents with additional patents pending worldwide for its drug delivery formulation and processing platform technology, according to the company's statement.

You May Also Be Interested In

• DBV Technologies refreshes ATM program with $150M ADS offering
• Regenxbio prices $100M public offering of stock and warrants
• ACI Worldwide exploring sale of billing division - Reuters